AbCellera partners with Lilly for antibody discovery

By The Science Advisory Board staff writers

May 26, 2020 -- AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

Under the strategic research collaboration and licensing agreement, AbCellera will use its antibody drug discovery platform to identify antibodies for therapeutic targets selected by Lilly. Lilly will also hold the rights to develop and commercialize any therapeutic products that are developed from the collaboration.

An initial joint effort, which was announced in March, has focused on co-developing antibody therapeutics for the possible prevention and treatment of COVID-19. Up to eight additional therapeutic targets can now be selected by Lilly, according to AbCellera.

AbCellera has received an upfront payment as part of the new contract, and will also be awarded research payments for the nonCOVID-19 targets, according to the firm. In addition, the company will be eligible for preclinical, clinical, and commercial milestone payments, as well as tiered royalties on future sales.

AbCellera secures COVID-19 drug development funding
AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
ESMO Virtual Congress 2020
September 14-29
2020 ACCP Annual Meeting
September 20-22
BioProcess International West
September 21-25
BioProcess International
September 21-25
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter